AIDS

1. KAMPHUIS AEM, Kiezebrink T, Waalewijn H, Bamford A, et al
   Pharmacokinetics of lopinavir/ritonavir in second-line treatment of children living with HIV in the CHAPAS-4 trial.
   AIDS. 2025 Aug 26. doi: 10.1097/QAD.0000000000004328.
   

   >> Share

   
   

   
   Clin Infect Dis

2. FIGUEROA MI, Brites C, Cecchini D, Ramalho A, et al
   Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study.
   Clin Infect Dis. 2025 Aug 28:ciaf415. doi: 10.1093.
   

   >> Share

   
   
3. WATERS LJ
   DOLCE: Sweet Success for Dolutegravir/Lamivudine?
   Clin Infect Dis. 2025 Aug 28:ciaf416. doi: 10.1093.
   

   >> Share

   
   

   
   J Infect Dis

4. LABARILE M, Schoepf IC, Pasin C, Oumelloul MA, et al
   Untargeted Metabolite Profile Associations with Body Mass Index, Waist-Hip Ratio, and Antiretroviral Therapy in >1300 People with HIV: the Swiss HIV Cohort Study.
   J Infect Dis. 2025 Aug 27:jiaf438. doi: 10.1093.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share